Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 283069

Gemcitabine in the first and second-line chemotherapy of advanced non-small cell lung cancer.


Čučević, Branka; Šamardžija, Mirko; Baričević, Dario; Jakopović, Marko; Redžepi, G.; Šamija, Mirko
Gemcitabine in the first and second-line chemotherapy of advanced non-small cell lung cancer. // Collegium Antropologicum, 29 (2005), 2; 583-8 (podatak o recenziji nije dostupan, članak, ostalo)


CROSBI ID: 283069 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Gemcitabine in the first and second-line chemotherapy of advanced non-small cell lung cancer.

Autori
Čučević, Branka ; Šamardžija, Mirko ; Baričević, Dario ; Jakopović, Marko ; Redžepi, G. ; Šamija, Mirko

Izvornik
Collegium Antropologicum (0350-6134) 29 (2005), 2; 583-8

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, ostalo

Ključne riječi
advanced non-small cell lung cancer; gemcitabine

Sažetak
Aim of this study was to estimate efficacy of gemcitabine in first and the second-line chemotherapy for patients with advanced non-small cell lung cancer (stage III and IV). In first-line chemotherapy, 120 patients were treated with different chemotherapy regimens. Fifty-nine patients were treated with gemcitabine / cisplatin (PG), 41 with cisplatin / etoposide (PE) and 20 with mitomycin / ifosfamide / cisplatin (MIC). Forty patients, unsuccessfully treated with PE and MIC in first-line therapy were treated with PG (24 pts) and with best supportive care (BSC) (16 pts). In first-line therapy PG was superior to PE and MIC protocol (mean survival (MS) 10 vs. 7 vs. 8.5 months). Response rate (RR) for PG in first-line therapy was 46% and 21% in second-line. We showed also significantly better survival in patients treated with PG in second-line chemotherapy comparing to best supportive care (MS 9 vs. 5.5 months). Toxic side effects for combination PG was acceptable. This study confirmed that PG combination is safe and effective as first and second-line chemotherapy for patients with advanced non-small cell lung cancer.

Izvorni jezik
Engleski



POVEZANOST RADA


Projekti:
0074008

Ustanove:
Klinika za tumore


Citiraj ovu publikaciju

Čučević, Branka; Šamardžija, Mirko; Baričević, Dario; Jakopović, Marko; Redžepi, G.; Šamija, Mirko
Gemcitabine in the first and second-line chemotherapy of advanced non-small cell lung cancer. // Collegium Antropologicum, 29 (2005), 2; 583-8 (podatak o recenziji nije dostupan, članak, ostalo)
Čučević, B., Šamardžija, M., Baričević, D., Jakopović, M., Redžepi, G. & Šamija, M. (2005) Gemcitabine in the first and second-line chemotherapy of advanced non-small cell lung cancer.. Collegium Antropologicum, 29 (2), 583-8.
@article{article, year = {2005}, pages = {583-8}, keywords = {advanced non-small cell lung cancer, gemcitabine}, journal = {Collegium Antropologicum}, volume = {29}, number = {2}, issn = {0350-6134}, title = {Gemcitabine in the first and second-line chemotherapy of advanced non-small cell lung cancer.}, keyword = {advanced non-small cell lung cancer, gemcitabine} }
@article{article, year = {2005}, pages = {583-8}, keywords = {advanced non-small cell lung cancer, gemcitabine}, journal = {Collegium Antropologicum}, volume = {29}, number = {2}, issn = {0350-6134}, title = {Gemcitabine in the first and second-line chemotherapy of advanced non-small cell lung cancer.}, keyword = {advanced non-small cell lung cancer, gemcitabine} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Social Science Citation Index (SSCI)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE





Contrast
Increase Font
Decrease Font
Dyslexic Font